Xiu-Fang Li, Chen-Fu Liu and Guo-Wu Rao* Pages 3339 - 3360 ( 22 )
Overexpression of human epidermal growth factor receptor (HER)-2 is found in a variety of cancers, often portending poor clinical outcomes. Therefore, HER2 is an attractive target for treatment. This review describes the research progress of HER2 targeted inhibitors in recent years. Excellent reviews are available, so we focus on the development, mechanisms of action, and structure-activity relationships of different types of inhibitors, including monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates (ADCs). In addition, the differences among them are compared.
HER2, ErbB2, tyrosine kinase, inhibitors, monoclonal antibody, antibody-drug conjugate.
College of Pharmaceutical Science, Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, College of Pharmaceutical Science, Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014